Akre Capital Management SOPH trades
Chuck Akre
Chuck Akre SOPHIA GENETICS SA stake
total: 85
Trades details
- Total transactions:
- 4
- New positions:
- 1
- Added:
- 3
- Held since:
- 2024 Q1
- Held for:
- 10 quarters
- Latest activity:
- 2025 Q2
According to 2026 Q2 report, Chuck Akre holds 3,719,140 SOPHIA GENETICS SA (SOPH) shares with a market value of roughly $21.46M accounting for 0.42% of the overall portfolio. To date, the estimated cost basis is nearly $3.94 for "buy" trades. Akre Capital Management first purchased SOPH in 2024 Q1, initially acquiring 287,699 shares. Since the initial investment in SOPHIA GENETICS SA (SOPH), Akre Capital Management has made 3 more transactions.
When did Chuck Akre buy SOPHIA GENETICS SA (SOPH)?
Chuck Akre first invested in SOPHIA GENETICS SA (SOPH) in 2024 Q1 at the reported quarter-end price of $4.93 per share.
What's the cost basis of Akre Capital Management's SOPH stake?
The estimated cost basis for SOPHIA GENETICS SA (SOPH) stake is around $3.94 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $3.94
Chuck Akre's historical trades in SOPHIA GENETICS SA
4 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2025 Q2
|
0.11%
|
3,719,140
|
$3.10
|
$11,529,334
|
+66.22% (+1,481,636)
|
+0.04%
|
|
2024 Q3
|
0.07%
|
2,237,504
|
$3.65
|
$8,166,890
|
+16.51% (+317,072)
|
+0.01%
|
|
2024 Q2
|
0.08%
|
1,920,432
|
$4.58
|
$8,795,579
|
+567.51% (+1,632,733)
|
+0.07%
|
|
2024 Q1
|
0.01%
|
287,699
|
$4.93
|
$1,418,356
|
new
|
+0.01%
|
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.